| Gene symbol | NR3C1 | Synonyms | GCCR, GCR, GCRST, GR, GRL | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | nuclear receptor subfamily 3 group C member 1 | ||||
| GTO ID | GTC0578 |
| Trial ID | 2013-002172-40 |
| Disease | Type 2 Diabetes Mellitus |
| Altered gene | NR3C1 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 426115|ISIS-GCCRRx |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneously Once Weekly for 6 Weeks to Patients with Type 2 Diabetes Mellitus Being Treated with Metformin |
| Year | 2014 |
| Country | Romania |
| Company sponsor | Isis Pharmaceuticals, Inc. |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||